☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - December 2016

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Ferric maltol (Feraccru®) has been rejected for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD). The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance.

Hydrocortisone (Plenadren®) has been rejected for use in the treatment of adrenal insufficiency in adults. The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - December 2016' by emailShare 'SMC Update - December 2016' on FacebookShare 'SMC Update - December 2016' on TwitterShare 'SMC Update - December 2016' on LinkedInShare 'SMC Update - December 2016' on reddit


No Comments to “SMC Update - December 2016”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.